GUTS FRACTYL HEALTH INC revenue, earnings and financials
For the quarter ended June 30, 2026, FRACTYL HEALTH INC reported revenue of n/a, net income of −$25.5M and diluted EPS of −$0.16; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.
GUTS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$96.8M, net income −$141M (margin n/a), EPS −$1.86
- Fiscal year ended Dec 2024: revenue $93.0K, gross profit $43.0K, operating income −$93.5M, net income −$68.7M (margin -73864.5%), EPS −$1.62
- Fiscal year ended Dec 2023: revenue $120K, gross profit $43.0K, operating income −$50.8M, net income −$77.1M (margin -64242.5%), EPS −$45.29
GUTS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.5M, EPS −$0.16
- Quarter ended Mar 31, 2026: revenue n/a, net income $9.22M, EPS $0.06
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$43.7M, EPS −$0.09
- Quarter ended Sep 30, 2025: revenue n/a, net income −$45.6M, EPS −$0.71
- Quarter ended Jun 30, 2025: revenue n/a, net income −$27.9M, EPS −$0.57
- Quarter ended Mar 31, 2025: revenue n/a, net income −$23.7M, EPS −$0.49
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.00K (down 57.1% year over year), net income −$25.0M, EPS −$0.61
- Quarter ended Sep 30, 2024: revenue $14.0K (down 61.1% year over year), net income −$23.2M, EPS −$0.48
- Quarter ended Jun 30, 2024: revenue $43.0K (down 40.3% year over year), net income −$17.2M, EPS −$0.36
- Quarter ended Mar 31, 2024: revenue $33.0K (up 560.0% year over year), net income −$3.32M, EPS −$0.17
- Quarter ended Dec 31, 2023 (from the annual report): revenue $7.00K, net income −$19.2M, EPS −$11.19
- Quarter ended Sep 30, 2023: revenue $36.0K, net income −$15.7M, EPS −$9.61
- Quarter ended Jun 30, 2023: revenue $72.0K, net income −$30.2M, EPS −$16.62
- Quarter ended Mar 31, 2023: revenue $5.00K, net income −$11.9M, EPS −$7.87
GUTS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$90.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$65.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$42.8M, share buybacks n/a
GUTS balance sheet
- Jun 30, 2026: cash $47.1M, total assets $82.0M, total liabilities $83.6M, shareholders' equity −$1.67M
- Mar 31, 2026: cash $63.2M, total assets $99.4M, total liabilities $78.0M, shareholders' equity $21.4M
- Dec 31, 2025: cash $81.5M, total assets $121M, total liabilities $112M, shareholders' equity $9.46M
- Sep 30, 2025: cash $77.7M, total assets $114M, total liabilities $117M, shareholders' equity −$3.18M
- Jun 30, 2025: cash $22.3M, total assets $62.0M, total liabilities $80.2M, shareholders' equity −$18.2M
- Mar 31, 2025: cash $42.1M, total assets $83.0M, total liabilities $76.7M, shareholders' equity $6.38M
- Dec 31, 2024: cash $67.5M, total assets $108M, total liabilities $79.7M, shareholders' equity $28.4M
- Sep 30, 2024: cash $84.7M, total assets $127M, total liabilities $76.6M, shareholders' equity $50.3M
What is GUTS's revenue?
FRACTYL HEALTH INC reported $0 of revenue for the fiscal year ended December 2025.
Is GUTS profitable?
No. FRACTYL HEALTH INC lost $106M over the last four quarters.
What is GUTS's EPS?
Diluted earnings per share over the last four quarters were −$0.90; −$0.16 in the latest quarter.